<DOC>
	<DOCNO>NCT02960854</DOCNO>
	<brief_summary>A study evaluate safety , tolerability pharmacokinetics Nivolumab participant severe sepsis septic shock .</brief_summary>
	<brief_title>A Study Nivolumab Safety Pharmacokinetics Patients With Severe Sepsis Septic Shock .</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Men woman age â‰¥ 18 year old Documented suspect infection Severe sepsis septic shock least 24 hour Sepsisinduced immunosuppression In Intensive Care Unit ( ICU ) plan discharge next 24 hour Previous episode severe sepsis septic shock ICU admission current hospitalization Autoimmune disease Organ bone marrow transplant Cancer treatment past 6 week Human immunodeficiency virus ( HIV ) infection therapy prior episode sepsis ; hepatitis C virus ( HCV ) infection still virus ( cure ) ; Chronic hepatitis B virus ( HBV ) infection treatment Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>